Evommune, Inc.EVMN
ImmunologyNeurology33 cited findings · profile updated 2026-08-25
13.79 USDnot live — refreshed daily
About Evommune, Inc.
Evommune, Inc. (EVMN) focuses on immunology and neurology. In immunology, EVO756's primary endpoint was percent change in Eczema Area and Severity Index (EASI) from baseline at Week 12. However, EVO756 did not meet its primary endpoint for Urticaria Activity Score over seven days (UAS7).
In neurology, EVO756 is undergoing a global Phase 2b trial for migraine prophylaxis, with an enrollment of 330 patients. This trial has a treatment duration of 12 weeks and a maximum daily dose of 100 mg. The primary endpoint for EVO756 in migraine prophylaxis is the mean change from baseline in monthly migraine days (MMD). Top-line data for EVO756 are expected in 2027. EVO301 has shown positive Phase 2a data and is slated for a Phase 2b trial.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Primary endpoint | percent change in Eczema Area and Severity Index (EASI) from baseline at Week 12 | Evommune, Inc. — SEC 8-K (2026-08-06), p.1 |
| Urticaria Activity Score over seven days (UAS7) | did not meet primary endpoint | Evommune, Inc. — SEC 8-K (2026-08-06), p.2 |
| Phase | Phase 2b | Evommune, Inc. — SEC 8-K (2026-08-06), p.2 |
| Number of patients | 330 | Evommune, Inc. — SEC 8-K (2026-08-06), p.2 |
| Treatment duration | 12 weeks | Evommune, Inc. — SEC 8-K (2026-08-06), p.2 |
| Maximum daily dose | 100 mg | Evommune, Inc. — SEC 8-K (2026-08-06), p.2 |
Key projects
- EVO756 (Eczema)
The primary endpoint for EVO756 was percent change in Eczema Area and Severity Index (EASI) from baseline at Week 12.
- EVO756 (Urticaria)
EVO756 did not meet its primary endpoint for Urticaria Activity Score over seven days (UAS7).
- EVO756 (migraine prophylaxis) — Global
EVO756 is in a Phase 2b global, randomized, double-blind, placebo-controlled, dose-ranging study for migraine prophylaxis with 330 patients.
- EVO301
EVO301 has positive Phase 2a data and is moving to Phase 2b.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Neurology research library →